Peter Woodford

Lein Applied Diagnostics Ltd. develops and provides optical measurement and non-invasive diagnostics products. It offers Dione, a compact and source and detector module that can be used as a scanning or static device, allowing position and multi-layer thickness measurements with sub-micron precision and repeatability; ICon and ICon SL (Scanning Lens) are non-contact position and multi-layer thickness measurement systems that are designed to measure an array of different materials, and CTS2, a non-contact thickness measurement system designed to measure three dimensional (3D) engineered tissues and cells. The company was founded by Graeme Lawrence Clark and Daniel John Daly in May 2003 and is headquartered in Reading, the United Kingdom.

iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom.

Molecular Vision Ltd. develops low-cost, lab-quality, point of care, disposable diagnostic devices for medical testing. The company was founded by Donal D. C. Bradley in 2001 and is headquartered in York, the United Kingdom.

Roche Diagnostics Ltd. manufactures equipment and reagents for research and medical diagnostic applications. The company was founded on September 14, 1956 and is headquartered in Burgess Hill, the United Kingdom.

Applied Physiology developed and commercializes guidance devices for use in the critical care environment. Navigator™, the flagship product, focuses on hemodynamic management. Applied Physiology aims to develop products that make life easier for the clinician. The devices continuously acquire physiological data from conventional monitors and use it to create a graphical depiction of the patient position, and continuous advice on the next therapy. Applied Physiology's devices enable the implementation of targeted therapy to optimize care and outcomes. The clinician specifies target ranges for the variables being monitored. The devices graphically display the patient position in relation to these targets, and indicate a course of therapy that will guide the patient to the target area. This self-adaptive protocol facilitates a safe and systematic approach to bedside care, where whole teams work toward a unified goal. Applied Physiology's therapeutic guidance devices have demonstrated potential benefits for both clinicians and patients: Clinical teamwork is enhanced and goals unified, Improved patient put comes, Reduced length of stay and Reduced morbidity in critical care units. At the heart of Applied Physiology's technology are mathematical algorithms based on a combination of systems physiology and control engineering methods. This rigorous basis has enabled the development of sound and reliable patient-specific solutions to treatment planning problems that are often counter-intuitive. Applied Physiology's flagship product Navigator™, which targets pressure and flow in the circulatory system, will be available for sale in Europe and Australia in the second quarter 2010. It will be available for sale in the U.S. pending regulatory approval from the FDA. The company is based Australia, and established European operations in the UK in 2008.

Part of Roche Holding AG, Roche Diabetes Care AG is a Swiss company that specializes in diabetes management through an integrated portfolio of glucose monitoring systems, lancing devices, insulin delivery systems, and digital solutions. The company is based in Burgdorf, Switzerland. Roche is one of the world's largest biotech companies and a leading provider of in-vitro diagnostics, offering transformative innovative solutions across major disease areas. The company's focus on finding innovative solutions for unmet medical needs is at the heart of their mission, with their ideas and research helping to save lives.